Cardiomyopathy

We spotlight 5 impactful regulatory decisions scheduled to occur during the first quarter of 2025.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

Greg Duck, PA-C shared insights from his CAPP 2024 presentation on tailoring medical management and effective treatment of methamphetamine-induced cardiomyopathy.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.

With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.

Milind Desai, MD describes favorable real-world safety outcomes from mavacamten use over 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program.

Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.

Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.

Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.

Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.

A single dose of nex-z achieved consistent and rapid reductions in serum TTR levels over 12 months of follow-up in patients with ATTR-CM.

Masri discussed the new phase 3 trial of Intellia’s NTLA-2001 or nex-z.

Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.

The sNDA submission to the FDA included a Priority Review Voucher, which commits the regulatory agency to an accelerated review timeline.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.

Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.

MAVA-LTE trial data show mavacamten's sustained benefits in symptomatic obstructive HCM, with long-term improvements in LVOT, NT-proBNP, and quality of life.

HELIOS-B trial shows vutrisiran reduces all-cause mortality and CV events in ATTR-CM, with benefits consistent regardless of tafamidis use.